相关实验视频
Updated: Jul 21, 2025

12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
34.6K
目前对CTLA-4的理解:从机制到自身免疫性疾病
Md Munnaf Hossen1,2,3, Yanmei Ma1,2,3, Zhihua Yin1,3
1Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China.
Frontiers in immunology
|July 27, 2023
概括
细胞毒性T淋巴细胞抗原4 (CTLA-4) 调节免疫反应并维持自身免疫沉默. 这篇评论探讨了CTLA-4的情况.
科学领域:
- 免疫学 免疫学 免疫学
- 这是一种自身免疫力.
- 分子生物学分子生物学
背景情况:
- 自身免疫性疾病 (ADs) 涉及对自身抗原的免疫反应,导致炎症.
- 细胞毒性T淋巴细胞抗原4 (CTLA-4) 是T细胞活性和免疫恒常的关键调节者.
- CTLA-4在抑制过度免疫反应和维持自我耐受性方面发挥着至关重要的作用.
研究的目的:
- 审查CTLA-4的结构,表达和信号通路.
- 阐明CTLA-4在调节自身免疫性疾病中的免疫反应中的作用.
- 总结针对CTLA-4针对各种AD的治疗潜力.
主要方法:
- 关于CTLA-4结构,功能和信号的文献综述.
- 分析CTLA-4与不同自身免疫性疾病之间的相关性.
- 目前关于CTLA-4作为治疗点的研究总结.
主要成果:
- CTLA-4降低了效应T细胞的活性,并增强了调节性T (Treg) 细胞的功能.
- CTLA-4与抑制各种ADS的发病,进展和病理学有关.
- 调节CTLA-4信号传递对于维持免疫平衡至关重要.
结论:
- CTLA-4是免疫反应的关键负调节剂,是预防自身免疫的关键因素.
- 了解CTLA-4的作用,可以了解ADs的病原性.
- CTLA-4是治疗自身免疫性疾病的一个有前途的治疗点.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Autoimmune Disorders
498
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
498
T Cell Activation and Clonal Selection
812
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
812
Cell-mediated Immune Responses
68.9K
Overview
68.9K
B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174

